- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07517705
MRD-Adaptált Alacsony Dózisú Sugárterápia Első Vonalbeli Kemóimmunoterápia Során Diffúz Nagy B-sejtes Lymphomában (MRD-XRT)
Az MRD-adaptált cikluson belüli kis dózisú sugárterápia együttes alkalmazásának megvalósíthatósága elsővonalas R-kemoimmunoterápiával diffúz nagy B-sejtes limfómában (MRD XRT)
This prospective Phase IIA feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline R-chemoimmunotherapy. Circulating tumor DNA (ctDNA)-based MRD testing and interim positron emission tomography (PET) imaging after two cycles of therapy are used to guide treatment decisions. Patients with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard systemic therapy. Patients with undetectable MRD, or detectable MRD without targetable residual disease, continue standard frontline chemoimmunotherapy without protocol-directed LDRT.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Diffuse large B-cell lymphoma (DLBCL) is commonly treated with frontline R-chemoimmunotherapy regimens such as R-CHOP or related combinations. Interim positron emission tomography (PET) imaging provides information about treatment response, while circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing allows assessment of molecular residual disease during treatment.
This prospective, non-randomized Phase IIA feasibility study evaluates the integration of ctDNA-based MRD testing and interim PET imaging into frontline treatment decisions for patients with DLBCL. Approximately 50 participants are expected to enroll.
Following two cycles of frontline R-chemoimmunotherapy, participants undergo protocol-specified MRD testing and interim PET assessment. Participants with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy are assigned to Arm A and receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard frontline chemoimmunotherapy.
Participants with undetectable MRD, as well as those with detectable MRD but without targetable residual disease, are assigned to Arm B and continue standard frontline chemoimmunotherapy without protocol-directed LDRT.
The primary objective is to evaluate the feasibility of this MRD-adapted strategy, including successful completion of MRD testing after cycle 2 and delivery of protocol-directed LDRT to eligible MRD-positive participants. Secondary assessments include treatment response, progression-free survival, overall survival, the impact of LDRT on systemic treatment delivery, and patient-reported quality of life.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Krishna vamsi Gottipati, MS
- Telefonszám: (402) 5593518
- E-mail: krgottipati@unmc.edu
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: IIT Office Clinical Trails Office
- Telefonszám: (402) 5590963
- E-mail: IITOFFICE@unmc.edu
Tanulmányi helyek
-
-
Nebraska
-
Omaha, Nebraska, Egyesült Államok, 68198
- Fred & Pamela Buffet Cancer Center
-
Kapcsolatba lépni:
- Snegha Ananth, MBBS
- Telefonszám: (402)559-3848
- E-mail: sananth@unmc.edu
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Adults ≥19 years of age
- Biopsy-proven newly diagnosed DLBCL, transformed from indolent lymphoma, Follicular lymphoma grade 3B, post-transplant lymphoproliferative disorder, or any other subtypes of Large B-cell lymphoma under WHO-HAEM5 classification who are eligible and plan to receive 6 cycles of R-chemoimmunotherapy. Note: patients may receive up to one cycle of R-chemoimmunotherapy prior to enrollment.
- Planned to receive 6 cycles of frontline R-chemoimmunotherapy for diseases mentioned in criterion 2
- Presence of measurable disease on imaging, nodal lesion >1.5cm or extra-nodal lesion >1 cm prior to initiation of R-chemoimmunotherapy
- Availability of sufficient and viable baseline FFPE tumor tissue to allow development of a personalized MRD assay
Exclusion Criteria:
- Limited stage (Ann Arbor stage I-II) DLBCL, requiring less than 6 cycles of R-chemoimmunotherapy
- Primary or secondary CNS lymphoma
- Subject has exceeded maximum lifelong cumulative doses of radiation therapy or is unsafe for radiation therapy as determined by the investigator and/or radiation oncologist
- Pregnant and lactating patients
- Has received two or more cycles of R-chemoimmunotherapy relating to this disease
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Arm- A: MRD-Detectable with Protocol-Directed LDRT
Participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) to targetable residual disease sites in addition to standard frontline chemoimmunotherapy. |
Low-dose radiation therapy delivered to residual PET-avid disease sites identified after interim assessment with PET imaging and MRD testing. Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician. |
|
Aktív összehasonlító: Arm B: Standard Therapy Without Protocol-Directed LDRT
Participants with undetectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy, or participants with detectable MRD but without residual PET-avid or measurable disease suitable for radiation therapy, continue standard frontline chemoimmunotherapy without protocol-directed low-dose radiation therapy (LDRT). |
Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Feasibility of Real-Time MRD-Guided Treatment Strategy
Időkeret: From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
|
Feasibility will be assessed by the proportion of enrolled patients who successfully complete protocol-specified MRD testing after two cycles of chemoimmunotherapy and, among patients with detectable MRD, the proportion who successfully receive protocol-defined low-dose radiation therapy (LDRT). Feasibility will be considered acceptable if at least 80% of enrolled patients complete MRD testing and at least 80% of ctDNA-positive patients receive LDRT. |
From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Overall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates
Időkeret: At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
The proportion of participants achieving complete response (CR) or partial response (PR), with complete response rate assessed separately. Response will be evaluated using PET/CT imaging according to Lugano 2014 criteria. |
At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
|
Progression-Free Survival (PFS)
Időkeret: From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
Progression-free survival is defined as the time from initiation of frontline therapy until disease progression or death from any cause. PFS will be estimated using the Kaplan-Meier method. |
From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
|
Overall Survival (OS)
Időkeret: From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
Overall survival is defined as the time from initiation of frontline therapy until death from any cause. OS will be estimated using the Kaplan-Meier method. |
From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
|
Impact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy
Időkeret: From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
The impact of protocol-directed low-dose radiation therapy (LDRT) on the delivery of planned systemic chemoimmunotherapy will be assessed by treatment delays, dose reductions, omitted chemotherapy cycles, or premature discontinuation of systemic therapy attributable to LDRT. |
From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Időkeret: At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
|
Patient-reported quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), evaluating global health status, functional domains, and symptoms. |
At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Snegha Ananth, MBBS, University of Nebraska
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Patológiás folyamatok
- Neoplazmák
- Immunrendszeri betegségek
- Neoplazmák szövettani típus szerint
- Neoplasztikus folyamatok
- Nyirokrendszeri betegségek
- Limfoproliferatív rendellenességek
- Immunproliferatív rendellenességek
- Limfóma, non-Hodgkin
- Limfóma, B-sejt
- Limfóma
- Kóros állapotok, jelek és tünetek
- Hemikus és nyirokbetegségek
- Neoplazma, maradék
- Limfóma, nagy B-sejtes, diffúz
- Terápiás kezelés
- Sugárterápia
Egyéb vizsgálati azonosító számok
- 0342-26-FB
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .